Chronic human immunodeficiency virus type 1 (HIV-1) disease is characterized by the retention of provirus within latently infected cells. Anti-HIV-1 CRISPR-Cas9 gene editing is an attractive strategy to excise or inactivate the HIV-1 genome. Recent strategies have focused on designing gRNAs that target the long terminal repeat (LTR) because 5′ and 3′ LTR symmetry can facilitate proviral excision. However, the promiscuity of CRISPR-Cas9 gene editing system necessitates the investigation of potential off-target effects. Here, potential gRNAs designed from HIV-1 phylogenetic subtypes using the CRISPRseek tool were investigated. Across the LTR, it was found that certain regions show higher human homology than others. When using recommended cutoffs, 96.40% of gRNAs were predicted to have no high probability off-target effects. Given this observation, while high-probability off-target effects are a potential danger, they can be avoided with proper gRNA design.
DelelisO, CarayonK, SaïbA, et al.Integrase and integration: biochemical activities of HIV-1 integrase. Retrovirology, 2008; 5:11–4. DOI: 10.1186/1742-4690-5-114.
4.
LoregianA, BortolozzoK, BosoS, et al.Interaction of Sp1 transcription factor with HIV-1 Tat protein: looking for cellular partners. FEBS Lett, 2003; 543:61–65. DOI: 10.1016/S0014-5793(03)00399-5.
5.
KretzschmarM, MeisterernstM, ScheidereitC, et al.Transcriptional regulation of the HIV-1 promoter by NF-kappa B in vitro. Genes Dev, 1992; 6:761–774. DOI: 10.1101/gad.6.5.761.
6.
RahaT, ChengSWG, GreenMR. HIV-1 Tat stimulates transcription complex assembly through recruitment of TBP in the absence of TAFs. PLoS Biol, 2005; 3:e4–4. DOI: 10.1371/journal.pbio.0030044.
7.
LiuY, NonnemacherMR, AlexakiA, et al.Functional studies of CCAAT/enhancer binding protein site located downstream of the transcriptional start site. Clin Med Insights Pathol, 2017; 10:11795557176945–5. DOI: 10.1177/1179555717694556.
8.
DahiyaS, LiuY, NonnemacherMR, et al.CCAAT enhancer binding protein and nuclear factor of activated T cells regulate HIV-1 LTR via a novel conserved downstream site in cells of the monocyte-macrophage lineage. PLoS One, 2014; 9:e8811–6. DOI: 10.1371/journal.pone.0088116.
9.
BurdoTH, NonnemacherM, IrishBP, et al.High-affinity interaction between HIV-1 Vpr and specific sequences that span the C/EBP and adjacent NF-κB sites within the HIV-1 LTR correlate with HIV-1-associated dementia. DNA Cell Biol, 2004; 23:261–269. DOI: 10.1089/104454904773819842.
10.
NonnemacherMR, IrishBP, LiuY, et al.Specific sequence configurations of HIV-1 LTR G/C box array result in altered recruitment of Sp isoforms and correlate with disease progression. J Neuroimmunol, 2004; 157:39–47. DOI: 10.1016/j.jneuroim.2004.08.021.
11.
ShahS, AlexakiA, PirroneV, et al.Functional properties of the HIV-1 long terminal repeat containing single-nucleotide polymorphisms in Sp site III and CCAAT/enhancer binding protein site I. Virol J, 2014; 11:9–2. DOI: 10.1186/1743-422X-11-92.
12.
WangW, YeC, LiuJ, et al.CCR5 gene disruption via lentiviral vectors expressing Cas9 and single guided RNA renders cells resistant to HIV-1 infection. PLoS One, 2014; 9:e11598–7. DOI: 10.1371/journal.pone.0115987.
13.
XuL, YangH, GaoY, et al.CRISPR/Cas9-mediated CCR5 ablation in human hematopoietic stem/progenitor cells confers HIV-1 resistance in vivo. Mol Ther, 2017; 25:1782–1789. DOI: 10.1016/j.ymthe.2017.04.027.
14.
YuS, YaoY, XiaoH, et al.Simultaneous knockout of CXCR4 and CCR5 genes in CD4+ T cells via CRISPR/Cas9 confers resistance to both X4- and R5-tropic human immunodeficiency virus type 1 infection. Hum Gene Ther, 2018; 29:51–67. DOI: 10.1089/hum.2017.032.
15.
HouP, ChenS, WangS, et al.Genome editing of CXCR4 by CRISPR/cas9 confers cells resistant to HIV-1 infection. Sci Rep, 2015; 5:1557–7. DOI: 10.1038/srep15577.
16.
UedaS, EbinaH, KanemuraY, et al.Anti-HIV-1 potency of the CRISPR/Cas9 system insufficient to fully inhibit viral replication. Microbiol Immunol, 2016; 60:483–496. DOI: 10.1111/1348-0421.12395.
17.
WangZ, PanQ, GendronP, et al.CRISPR/Cas9-derived mutations both inhibit HIV-1 replication and accelerate viral escape. Cell Rep, 2016; 15:481–489. DOI: 10.1016/j.celrep.2016.03.042.
18.
ZhangY, YinC, ZhangT, et al.CRISPR/gRNA-directed synergistic activation mediator (SAM) induces specific, persistent and robust reactivation of the HIV-1 latent reservoirs. Sci Rep, 2015; 5:1–14. DOI: 10.1038/srep16277.
19.
SaaymanSM, LazarDC, ScottTA, et al.Potent and targeted activation of latent HIV-1 using the CRISPR/dCas9 activator complex. Mol Ther, 2016; 24:488–498. DOI: 10.1038/mt.2015.202.
20.
KaminskiR, ChenY, FischerT, et al.Elimination of HIV-1 genomes from human T-lymphoid cells by CRISPR/Cas9 gene editing. Sci Rep, 2016; 6:2255–5. DOI: 10.1038/srep22555.
21.
KaminskiR, BellaR, YinC, et al.Excision of HIV-1 DNA by gene editing: a proof-of-concept in vivo study. Gene Ther, 2016; 23:690–695. DOI: 10.1038/gt.2016.41.
22.
DampierW, SullivanNT, ChungC-H, et al.Designing broad-spectrum anti-HIV-1 gRNAs to target patient-derived variants. Sci Rep, 2017; 7:1441–3. DOI: 10.1038/s41598-017-12612-z.
23.
DampierW, SullivanNT, MellJ, et al.Broad spectrum and personalized gRNAs for CRISPR/Cas9 HIV-1 therapeutics. AIDS Res Hum Retroviruses, 2018;AID.2017.0274. DOI: 10.1089/AID.2017.0274.
24.
UleriE, MeiA, MameliG, et al.HIV Tat acts on endogenous retroviruses of the W family and this occurs via Toll-like receptor 4. AIDS, 2014; 28:2659–2670. DOI: 10.1097/QAD.0000000000000477.
25.
Gonzalez-HernandezMJ, CavalcoliJD, SartorMA, et al.Regulation of the human endogenous retrovirus K (HML-2) transcriptome by the HIV-1 Tat protein. J Virol, 2014; 88:8924–8935. DOI: 10.1128/JVI.00556-14.
26.
LeitnerT, HahnB, MullinsJ, et al.(eds) HIV Sequence Compendium. Los Alamos, NM: Theoretical Biology and Biophysics Group, Los Alamos National Laboratory, 2017.
27.
HsuPD, ScottDA, WeinsteinJA, et al.DNA targeting specificity of RNA-guided Cas9 nucleases. Nat Biotechnol, 2013; 31:827–832. DOI: 10.1038/nbt.2647.
28.
ZhuLJ, HolmesBR, AroninN, et al.CRISPRseek: a bioconductor package to identify target-specific guide RNAs for CRISPR-Cas9 genome-editing systems. PLoS One, 2014; 9:e10842–4. DOI: 10.1371/journal.pone.0108424.
29.
SieversF, WilmA, DineenD, et al.Fast, scalable generation of high-quality protein multiple sequence alignments using Clustal Omega. Mol Syst Biol, 2011; 7:53–9. DOI: 10.1038/msb.2011.75.
LanderES, LintonLM, BirrenB, et al.Initial sequencing and analysis of the human genome. Nature, 2001; 409:860–921. DOI: 10.1038/35057062.
32.
QuinlanAR, HallIM. BEDTools: a flexible suite of utilities for comparing genomic features. Bioinformatics, 2010; 26:841–2. DOI: 10.1093/bioinformatics/btq033.
33.
AfganE, BakerD, van den BeekM, et al.The Galaxy platform for accessible, reproducible and collaborative biomedical analyses: 2016 update. Nucleic Acids Res, 2016; 44:W3–W10. DOI: 10.1093/nar/gkw343.
34.
CockPJA, AntaoT, ChangJT, et al.Biopython: freely available Python tools for computational molecular biology and bioinformatics. Bioinformatics, 2009; 25:1422–1423. DOI: 10.1093/bioinformatics/btp163.
van der WaltS, ColbertSC, VaroquauxG. The NumPy array: a structure for efficient numerical computation. Comput Sci Eng, 2011; 13:22–30. DOI: 10.1109/MCSE.2011.37.
38.
TeamRC. R: a language and environment for statistical computing. Available online at https://www.r-project.org/ (accessed August4, 2018).
The Bioconductor Dev Team.. BSgenome.Hsapiens.UCSC.hg19: Full genome sequences for Homo sapiens (UCSC version hg19). DOI: 10.18129/B9.bioc.BSgenome.Hsapiens.UCSC.hg19 (accessed August4, 2018).
44.
CarlsonM and Bioconductor Package Maintainer. TxDb.Hsapiens.UCSC.hg19.knownGene: Annotation package for TxDb object(s). DOI: 10.18129/B9.bioc.TxDb.Hsapiens.UCSC.hg19.knownGene.
45.
CarlsonM. org.Hs.eg.db: Genome wide annotation for Human. DOI: 10.18129/B9.bioc.org.Hs.eg.db.
46.
ZeileisA, GrothendieckG. zoo: S3 infrastructure for regular and irregular time series. J Stat Softw, 2005; 14:1–30. DOI: 10.18637/jss.v014.i06.
DoenchJG, HartenianE, GrahamDB, et al.Rational design of highly active sgRNAs for CRISPR-Cas9–mediated gene inactivation. Nat Biotechnol, 2014; 32:1262–1267. DOI: 10.1038/nbt.3026.
51.
CohenCJ, LockWM, MagerDL. Endogenous retroviral LTRs as promoters for human genes: a critical assessment. Gene, 2009; 448:105–114. DOI: 10.1016/j.gene.2009.06.020.
52.
KämmererU, GermeyerA, StengelS, et al.Human endogenous retrovirus K (HERV-K) is expressed in villous and extravillous cytotrophoblast cells of the human placenta. J Reprod Immunol, 2011; 91:1–8. DOI: 10.1016/j.jri.2011.06.102.
53.
TselisA. Evidence for viral etiology of multiple sclerosis. Semin Neurol, 2011; 31:307–316. DOI: 10.1055/s-0031-1287656.
54.
FreimanisG, HooleyP, EjtehadiHD, et al.A role for human endogenous retrovirus-K (HML-2) in rheumatoid arthritis: investigating mechanisms of pathogenesis. Clin Exp Immunol, 2010; 160:340–347. DOI: 10.1111/j.1365-2249.2010.04110.x.
55.
AsuncionL, FogelgrenB, FongKSK, et al.A novel human lysyl oxidase-like gene (LOXL4) on chromosome 10q24 has an altered scavenger receptor cysteine rich domain. Matrix Biol, 2001; 20:487–491. DOI: 10.1016/S0945-053X(01)00161-5.
56.
JiangN, ZhanF, TanG, et al.A cDNA located on chromosome 7q32 shows loss of expression in epithelial cell line of nasopharyngeal carcinoma. Chin Med J (Engl), 2000; 113:650–653.
57.
HuangS, ZhangL, NiuQ, et al.Hypoxia promotes epithelial–mesenchymal transition of hepatocellular carcinoma cells via inducing GLIPR-2 expression. PLoS One, 2013; 8:e7749–7. DOI: 10.1371/journal.pone.0077497.
58.
KipreosET, PaganoM. The F-box protein family. Genome Biol, 2000; 1:reviews300–2.1. DOI: 10.1186/gb-2000-1-5-reviews3002.
59.
CraigKL, TyersM. The F-box: a new motif for ubiquitin dependent proteolysis in cell cycle regulation and signal transduction. Prog Biophys Mol Biol, 1999; 72:299–328. DOI: 10.1016/S0079-6107(99)00010-3.
60.
DampierW, NonnemacherMR, MellJ, et al.HIV-1 genetic variation resulting in the development of new quasispecies continues to be encountered in the peripheral blood of well-suppressed patients. PLoS One, 2016; 11:e015538–2. DOI: 10.1371/journal.pone.0155382.
61.
DaerRM, CuttsJP, BrafmanDA, et al.The impact of chromatin dynamics on Cas9-mediated genome editing in human cells. ACS Synth Biol, 2017; 6:428–438. DOI: 10.1021/acssynbio.5b00299.
62.
Uusi-MäkeläMIE, BarkerHR, BäuerleinCA, et al.Chromatin accessibility is associated with CRISPR-Cas9 efficiency in the zebrafish (Danio rerio). PLoS One, 2018; 13:e019623–8. DOI: 10.1371/journal.pone.0196238.
63.
TsaiSQ, ZhengZ, NguyenNT, et al.GUIDE-seq enables genome-wide profiling of off-target cleavage by CRISPR-Cas nucleases. Nat Biotechnol, 2015; 33:187–197. DOI: 10.1038/nbt.3117.
64.
TsaiSQ, NguyenNT, Malagon-LopezJ, et al.CIRCLE-seq: a highly sensitive in vitro screen for genome-wide CRISPR–Cas9 nuclease off-targets. Nat Methods, 2017; 14:607–614. DOI: 10.1038/nmeth.4278.
Supplementary Material
Please find the following supplemental material available below.
For Open Access articles published under a Creative Commons License, all supplemental material carries the same license as the article it is associated with.
For non-Open Access articles published, all supplemental material carries a non-exclusive license, and permission requests for re-use of supplemental material or any part of supplemental material shall be sent directly to the copyright owner as specified in the copyright notice associated with the article.
